1.
Capes A, Rossoni C, Gat E, Cartron G, Gros F-X, Bachy E, Manson G, Brisou G, Thieblemont C, Guidez S, La Rochelle LD, Dulery R, Malard F, Jardin F, Tessoulin B, Le Bras F, Morschhauser F, Durand A, Llorente CC, Bories P, Loschi M, Choquet S, Damaj G-L, Rubio M-T, Tanguy-Schmidt A, Bay J-O, Joris M, Carras S, Lebras L, Abraham J, Malfuson J-V, Fouillet L, Hermine O, Chauchet A, Herbreteau L, Guffroy B, Decroocq J, Le Gouill S, Houot R, Bourbon E. Characterization and impact of response to holding/bridging therapy in second-line large B-cell lymphoma patients treated with axicabtagene ciloleucel: a LYSA study from the French DESCAR-T registry. Haematologica; https://doi.org/10.3324/haematol.2026.301559 [Early view].